| 9.23 0.46 (5.25%) | 09-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.15 | 1-year : | 19.83 |
| Resists | First : | 13.83 | Second : | 16.97 |
| Pivot price | 10.46  |
|||
| Supports | First : | 8.73 | Second : | 7.27 |
| MAs | MA(5) : | 9.47 |
MA(20) : | 11.22 |
| MA(100) : | 12.48 |
MA(250) : | 7.43 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 4 |
| RSI | RSI(14): 26.6 |
|||
| 52-week | High : | 23.56 | Low : | 1.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ QTTB ] has closed above bottom band by 12.9%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.44 - 9.5 | 9.5 - 9.56 |
| Low: | 8.64 - 8.71 | 8.71 - 8.77 |
| Close: | 9.13 - 9.23 | 9.23 - 9.32 |
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Sat, 26 Sep 2026
Q32 Bio: Durable Hair Regrowth Remains The Goal (NASDAQ:QTTB) - Seeking Alpha
Tue, 22 Sep 2026
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet - Eastern Progress
Mon, 14 Sep 2026
700,000 face alopecia as Q32 Bio (QTTB) hires drug veterans - Stock Titan
Mon, 07 Sep 2026
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround - finance.yahoo.com
Mon, 24 Aug 2026
Q32 Bio: The Efficacy Is Modest, The Valuation Is Not (NASDAQ:QTTB) - Seeking Alpha
Mon, 20 Jul 2026
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 76.2 (%) |
| Shares Short | 3,140 (K) |
| Shares Short P.Month | 2,260 (K) |
| EPS | 3.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.46 |
| Profit Margin | 62.8 % |
| Operating Margin | 39.9 % |
| Return on Assets (ttm) | 14.7 % |
| Return on Equity (ttm) | 72.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.32 |
| Sales Per Share | 1.8 |
| EBITDA (p.s.) | 0.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | 19 (M) |
| PE Ratio | 2.93 |
| PEG Ratio | 0 |
| Price to Book value | 2.06 |
| Price to Sales | 5.11 |
| Price to Cash Flow | -13.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|